Health Canada — Medical Devices · Canada · 2023-06-22 · Type II
🏛Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked above. No AI-generated text appears on this page. How we use AI →
Reported risk: Vanta Implantable Neurostimulator (INS) may malfunction after a cardioversion or defrbrillation procedure. The damage/malfunction to the device may no longer allow it to provide therapy or communicate with applications, resulting in a loss of stimulation and the need for an unanticipated surgery to explant/replace the INS. Recall start date : June 6, 2023
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.